Could immunotherapy finally break through in prostate cancer?
Author:
- Anthony KingAKAnthony King
- 14 September 2022
- journal article
- editorial
- Published by Springer Nature in Nature
- Vol. 609 (7927) , S42-S44
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Androgen receptor activity in T cells limits checkpoint blockade efficacyNature, 2022
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialNature Medicine, 2022
- 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)Annals of Oncology, 2020
- 616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)Annals of Oncology, 2020
- A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJournal for ImmunoTherapy of Cancer, 2020
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2019
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate CancerJNCI: Journal of the National Cancer Institute, 2014
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010